Big Idea Ventures, global leader in early-stage investments in the alternative protein sector, revealed its latest accelerator cohort today. Seventeen early-stage startups were selected for pre-seed investment as part of Big Idea Ventures bi-annual new protein accelerator program.
BOSTON, Oct. 4, 2022 Ginkgo Bioworks (DNA), the leading horizontal platform for cell programming, today announced the tuck-in acquisition of Circularis, a biotechnology company with a proprietary circular RNA and promoter screening platform.
BOSTON, Oct. 4, 2022 Ginkgo Bioworks (DNA), the leading horizontal platform for cell programming, today announced the tuck-in acquisition of Altar, a French biotechnology company that has developed a proprietary adaptive evolution platform.
NEW YORK, Oct. 3, 2022 The latest market analysis report titled Immunosuppressants Market by Drug Class and Geography - Forecast and Analysis 2022-2026 has been added to Technavio's catalog. For more analysis on Vendor Offerings - Read our Sample Report Immunosuppressants Market Segmentation Detail Insights on the impact of each segment and make informed business decisions.
The AL amyloidosis market is expected to show positive growth owing to the factors such as increased incidence and the anticipated launch of novel therapies during the forecast period.
Acquisition adds breakthrough calcitonin gene-related peptide portfolio, including NURTEC® ODT, to address needs of millions of migraine patients worldwide Pfizer Inc. (PFE) announced today the completion of its acquisition of Biohaven Pharmaceutical Holding Company Ltd. (BHVN), the maker of NURTEC® ODT, an innovative migraine therapy approved for both acute treatment and prevention of episodic migraine i...
Founder of several public life sciences companies including Questcor, Osteologix and Indevus, Casamento will serve as an Independent Director via NewMediaWire PaxMedica, Inc. (PXMD), a clinical-stage biopharmaceutical company focused on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms such as autism spectrum disease, today announc...
Tradeup Acquisition Corp (UPTD): * ESTRELLA BIOPHARMA, INC., A BIOPHARMACEUTICAL COMPANY TO BECOME A PUBLICLY TRADED COMPANY VIA MERGER WITH Tradeup Acquisition Corp (UPTD). * ESTRELLA BIOPHARMA, INC., A BIOPHARMACEUTICAL COMPANY TO BECOME A PUBLICLY TRADED COMPANY VIA MERGER WITH Tradeup Acquisition Corp (UPTD). * Tradeup Acquisition Corp (UPTD) - UPON CLOSING OF TRANSACTION, TRADEUP WILL BE RENAMED "ESTRELLA IMMUNOPHARM...
NEW YORK, Oct. 3, 2022 Estrella Biopharma, Inc., a preclinical-stage biopharmaceutical company focusing on cancer therapeutics, and TradeUP Acquisition Corp. (UPTD), a publicly traded special purpose acquisition company, today announced that they have entered into a definitive business combination agreement on September 30, 2022 that will result in Estrella becoming a publicly listed company.
News, commentary and research reports are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.
PDF’s require Adobe® Reader® and will open in a new window.
Log In Required
Line of Credit Log In Required